ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1267 • 2017 ACR/ARHP Annual Meeting

    Blood Pressure Control over Time in Childhood-Onset Systemic Lupus Erythematous

    Pinar Ozge Avar Aydin1, Jian Shan2, Hermine I. Brunner1 and Mark Mitsnefes3, 1Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Peking Union Medical College Hospital, Peking, China, Peking, China, 3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Cardiovascular disease (CVD) is the leading cause of increased long-term morbidity and mortality in systemic lupus erythematosus (SLE). As an important modifiable risk factor…
  • Abstract Number: 1268 • 2017 ACR/ARHP Annual Meeting

    Risk Factors for Bone Loss in Juvenile-Onset Systemic Lupus Erythematosus: A Prospective Study

    Luiz A Sousa1, Juliane Paupitz1, Nadia E Aikawa2, Liliam Takayama1, Valéria F. Caparbo1 and Rosa M R Pereira3, 1Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil, 3Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Juvenile-onset systemic lupus erythematosus (JoSLE) is associated with low bone mass for age and fractures, nevertheless risk factors and predictors of bone involvement are…
  • Abstract Number: 1269 • 2017 ACR/ARHP Annual Meeting

    Investigating Time Trends in Incident Pediatric Lupus across Ethnic Groups in Toronto, Canada—a Large, Multiethnic Metropolitan Area

    Laura Y Feldman1, Patrick Brown2, Linda T Hiraki1,3 and Earl Silverman3, 1Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, 2Department of Statistical Sciences, University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Lupus incidence rates are known to differ by ethnicity among children and adults, with African ancestry as a risk factor for incident lupus, compared…
  • Abstract Number: 1270 • 2017 ACR/ARHP Annual Meeting

    Comparison of Clinical and Serological Features of Juvenile and Adult-Onset Neuropsychiatric Lupus in Spanish Patients

    Sandra Garrote-Corral1, Alina Boteanu2, Walter A. Sifuentes-Giraldo1, Antía García-Fernández1, María Luz Gámir-Gámir1 and Antonio Zea Mendoza1, 1Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 2Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain

    Background/Purpose: Neuropsychiatric (NP) manifestations are a main cause of morbidity and mortality in juvenile-onset systemic lupus erythematosus (jSLE). Some studies suggest that they are more…
  • Abstract Number: 1271 • 2017 ACR/ARHP Annual Meeting

    Associations between Systemic Lupus Susceptibility (SLE) Loci and Anti-Phospholipid Antibody (aPL) Positivity in Childhood-Onset SLE (cSLE)

    Linda T Hiraki1,2, France Gagnon3, Earl Silverman2, Deborah M. Levy2, Sima Abu Alsaoud4 and Karl Everett1,3, 1Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, 2Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 3Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 4Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Genome-wide association studies have identified nearly 60 susceptibility loci for systemic lupus erythematosus (SLE). However, few studies have investigated their influence on specific disease…
  • Abstract Number: 1272 • 2017 ACR/ARHP Annual Meeting

    Cluster Analysis of Autoantibodies and Their Relationship with Demographic and Clinical Features in Pediatric Systemic Lupus Erythematosus in the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry

    Ginger Janow1, Uptej Khalsa2 and Tracy Andrews3, 1Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health Network, Hackensack, NJ, 2Pediatrics, Newark Beth Israel Medical Center, Children's Hospital of New Jersey, Newark, NJ, 3Research, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, heterogeneous, multisystem autoimmune disease characterized, in part, by the presence of autoantibodies. The spectrum of disease presents…
  • Abstract Number: 1273 • 2017 ACR/ARHP Annual Meeting

    Patient Health Questionnaire-9 Utilization for the Detection of Depression in Adolescents and Young Adults with Lupus Nephritis

    Peter Yorgin1, Eleanor Lazarow2 and Robert Sheets3, 1Pediatrics, Rady Children's Hospital/University of California San Diego, San Diego, CA, 2Social Work, Rady Children's Hospital, San Diego, CA, 3Pediatrics, Rady Children's Hospital/UCSD, San Diego, CA

    Background/Purpose:  The PHQ-9 is a self-administered depression screening questionnaire. Patients with a PHQ-9 score of 0-4 have no depression, 5-9, mild; 10-14, moderate; 15-19, moderately severe;…
  • Abstract Number: 1274 • 2017 ACR/ARHP Annual Meeting

    Anti-MDA5 Autoantibodies Associated with Juvenile Dermatomyositis Constitute a Distinct Phenotype in North America 

    Gulnara Mamyrova1, Takayuki Kishi2, Ira N Targoff3, Rodolfo V Curiel4, Frederick W Miller2 and Lisa G Rider2, 1Rheumatology, George Washington University School of Medicine and Health Sciences, Washington, DC, 2Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 3VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, 4George Washington University School of Medicine and Health Sciences, Washington, DC

    Background/Purpose: Anti-MDA5 autoantibodies (Abs) have been associated with clinically amyopathic and classic dermatomyositis (DM), with rapidly progressive interstitial lung disease (ILD) and poor prognosis in…
  • Abstract Number: 1275 • 2017 ACR/ARHP Annual Meeting

    101 Juvenile Myositis Patients Characterized By Myositis Specific Antibodies: Disease Activity and Damage over 60 Months

    Lauren M. Pachman1,2, Megan L. Curran3, Gabrielle A. Morgan4, IRA Targoff5, Hua Huang6, Dong Xu7 and Chiang-Ching Huang8, 1Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 2Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Pediatric Immunology/Rheum, UCSF, San Francisco, CA, 4Cure JM Program of Excellence in Myositis Research, Chicago, IL, 5internal Medicine, The University of Oklaoma, Norman, OK, 6Joseph J. Zilber School of Public Health, Milwaukee, WI, 7Pediatric Rheumatology, Stanley Manne Research Center, Chicago, IL, 8Biostatistics, Joseph J. Zilber School of Public Health,, Milwaukee, WI

    Background/Purpose: The impetus for this investigation was the specific questions from parents of JM patients pertaining to the physician’s expectations about their child’s disease course.…
  • Abstract Number: 1276 • 2017 ACR/ARHP Annual Meeting

    Nail Fold Capillary Changes Are Associated with Pulmonary, but Not with Cardiac Involvement in Juvenile Dermatomyositis

    Zoltán Barth1,2,3, Thomas Schwartz2,4, Berit Flatø5,6, Akos Koller7,8, May Brit Samersaw-Lund9, Ivar Sjaastad10,11 and Helga Sanner6, 1Bjorknes College, Oslo, Norway, 2Oslo University Hospital and University of Oslo, Institute for Experimental Medical Research, Oslo, Norway, 3Medical School, University of Pecs, Institute for Translational Medicine, Pecs, Hungary, 4Institute for Experimental Medical Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway, 5Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, 6Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, 7University of Physical Education, Institute of Natural Sciences, Budapest, Hungary, 8Medical School, University of Pecs, Department of Neurosurgery, Pecs, Hungary, 9Oslo University Hospital, Rikshospitalet, Department of Respiratory Medicine, Oslo, Norway, 10Department of Cardiology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 11Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway, Oslo, Norway

    Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune disease of unknown origin, characterised primarily by cutaneous rashes and symmetrical weakness of the proximal skeletal muscles.…
  • Abstract Number: 1277 • 2017 ACR/ARHP Annual Meeting

    Longitudinal Predictors of Physical Function in Juvenile Myositis

    Kaveh Ardalan1,2, Hannah L. Palac3,4, Julia (Jungwha) Lee4, Madison Wolfe5,6, Gabrielle A. Morgan7,8 and Lauren M. Pachman9, 1Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 3Abbvie, Inc, Chicago, IL, 4Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 5Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 6Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, 7Cure JM Program of Excellence in Myositis Research, Chicago, IL, 8Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 9Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

    Background/Purpose: Juvenile myositis (JM) is marked by skin rashes, proximal muscle weakness, and deconditioning causing potentially severe disability. Studies examining long-term physical function in JM…
  • Abstract Number: 1278 • 2017 ACR/ARHP Annual Meeting

    Growth and Puberty in Juvenile Dermatomyositis a Longitudinal Multinatinal Cohort Study

    Ellen Nordal1,2, Angela Pistorio3, Marite Rygg3, Gabriella Giancane4, Michaël Hofer3, Jose Antonio Melo-Gomes4, Blanca Bica4, Ximean Norambuena4, Valda Stanevicha3, Rebecca ten Cate5, Olga Vougiouka4, Jurgen Brunner4, Guenther Dannecker4, Polyxeni Pratsidou-Gertsi4, Gabriele Simonini4, Helen Venning4, Serena Pastore4, Angelo Ravelli6, Alberto Martini7 and Nicolino Ruperto7, 1Department of Pediatrics, University Hospital of Northern Norway, Tromsø, Norway, 2Department of Clinical medicine, UIT, the Arctic University of Norway, Tromsø, Norway, 3Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, 4Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, 5Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 6University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, 7Istituto Giannina Gaslini, Genoa, Italy

     Background/Purpose: Children with juvenile dermatomyositis (JDM) are at risk of growth failure and delayed puberty because of inflammatory disease activity and side effects of corticosteroid…
  • Abstract Number: 1279 • 2017 ACR/ARHP Annual Meeting

    Risk Factors for Achieving a Drug-Free Remission in Patients with Juvenile Dermatomyositis

    Tomokazu Nagakura1, Takuma Ito2, Masateru Kusuda2, Tuyoshi Yamatou2, Tomohiro Kubota2, Yuuichi Yamasaki2, Yukiko Nonaka2, Tomoko Takezaki2, Harumi Akaike3, Yasuhito Nerome2, Hiroyuki Imanaka2 and Syuji Takei4, 1Pediatrics, The Holy Mother of Grace Hospital Home for Children and Persons with Severe Motor and Intellectual Disabilities, Usuki, Japan, Usuki, Japan, 2Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshima, Japan, 3Department of Pediatrics, Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshima, Japan, 4Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshma, Japan

    Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children. Approximately one-third of JDM patients attain drug-free remission (DFR) without relapse; however,…
  • Abstract Number: 1280 • 2017 ACR/ARHP Annual Meeting

    Clinical Outcomes of Juvenile Dermatomyositis Patients Treated with TNF-Inhibitors: A Retrospective Chart Review Katelyn Banschbach1, Ellen Go1 and Stacey Tarvin2, 1Indiana University School of Medicine, 2riley Hospital for Children, Indiana University

    Katelyn Banschbach1, Ellen Go2 and Stacey Tarvin3, 1Indiana University School of Medicine, Indianapolis, IN, 2Pediatrics, Indiana University School of Medicine, Indianapolis, IN, 3Riley Hospital for Children, Indiana University, Indianapolis, IN

    Background/Purpose: To analyze the clinical outcomes of TNF-inhibitors as a steroid-sparing agent in the treatment of juvenile dermatomyositis (JDM). Methods: We performed a retrospective chart…
  • Abstract Number: 1281 • 2017 ACR/ARHP Annual Meeting

    Plasma CXCL4 As a Biomarker in Juvenile Systemic Sclerosis

    Katharine Moore1,2, Marvin J. Fritzler3, Marisa S. Klein-Gitelman4, Ann M Reed5, Tzielan Lee6 and Anne Stevens7,8, 1Pediatrics, University of Colorado, Aurora, CO, 2Pediatric Rheumatology, Children's Hospital Colorado, Aurora, CO, 3Medicine, University of Calgary, Calgary, AB, Canada, 4Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, 5Rheumatology, Duke University, Durham, NC, 6Pediatric Rheumatology, Stanford University, Palo Alto, CA, 7University of Washington, Department of Pediatrics, Seattle, WA, 8Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA

    Background/Purpose: Juvenile systemic sclerosis (jSSc) is a severe and heterogeneous autoimmune vasculopathy. Pulmonary fibrosis is the highest independent predictor of mortality, yet currently there are…
  • « Previous Page
  • 1
  • …
  • 1288
  • 1289
  • 1290
  • 1291
  • 1292
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology